Dear Editor, Cytomegalovirus (CMV) infection is a major complication in patients who undergo hematopoietic stem cell transplantation (HSCT); thus, surveillance of CMV infection or reactivation is widely performed to prevent disease progression. Although the CMV antigenemia test has long been used for CMV detection [1] , it has several limitations such as a requirement for fresh blood samples, subjective interpretation, and reduced feasibility in neutropenic patients [2] . Recently, CMV quantitative (Q)-PCR has emerged as an alternative to antigenemia testing [3] . Nevertheless, there is no universal threshold of circulating DNA values for initiating antiviral therapy in HSCT patients. In addition, the DNA values used to reflect the clinical course may vary among patients because of different therapeutic interventions and age effects. This is the first report to evaluate the relationship of the results of the CMV antigenemia testing and Q-PCR in different age groups of patients undergoing HSCT and to show the impact of age on this relationship. Our results may be useful to establish appropriate threshold values for pediatric and adult patients in similar clinical conditions. The antigenemia testing (CINA Kit system, Argene Biosoft, Varilhes, France) and Q-PCR (Real-Q CMV DNA quantification kit, BioSewoom, Seoul, Korea) using EDTA-treated whole blood derived DNA (MagNa Pure 96 DNA and Viral NA small volume kit, Roche, Manheim, Germany) were performed simultaneously in HSCT patients to monitor CMV infection at rospective data (2,474 results) were collected from 75 children and 173 adults. The DNA value was generated in standardized units of IU/mL. This study was approved by the Institutional Review Board of Samsung Medical Center (IRB No. SMC 2018-04-056-001), and informed consent was waived.
Dear Editor, Cytomegalovirus (CMV) infection is a major complication in patients who undergo hematopoietic stem cell transplantation (HSCT); thus, surveillance of CMV infection or reactivation is widely performed to prevent disease progression. Although the CMV antigenemia test has long been used for CMV detection [1] , it has several limitations such as a requirement for fresh blood samples, subjective interpretation, and reduced feasibility in neutropenic patients [2] . Recently, CMV quantitative (Q)-PCR has emerged as an alternative to antigenemia testing [3] . Nevertheless, there is no universal threshold of circulating DNA values for initiating antiviral therapy in HSCT patients. In addition, the DNA values used to reflect the clinical course may vary among patients because of different therapeutic interventions and age effects. This is the first report to evaluate the relationship of the results of the CMV antigenemia testing and Q-PCR in different age groups of patients undergoing HSCT and to show the impact of age on this relationship. Our results may be useful to establish appropriate threshold values for pediatric and adult patients in similar clinical conditions. The antigenemia testing (CINA Kit system, Argene Biosoft, Varilhes, France) and Q-PCR (Real-Q CMV DNA quantification kit, BioSewoom, Seoul, Korea) using EDTA-treated whole blood derived DNA (MagNa Pure 96 DNA and Viral NA small volume kit, Roche, Manheim, Germany) were performed simultaneously in HSCT patients to monitor CMV infection at Samsung Medical Center, Seoul, Korea, from June 2016 to December 2017. Retrospective data (2,474 results) were collected from 75 children and 173 adults. The DNA value was generated in standardized units of IU/mL. This study was approved by the Institutional Review Board of Samsung Medical Center (IRB No. SMC 2018-04-056-001), and informed consent was waived.
The relationship between the results of the antigenemia testing and Q-PCR was analyzed by Deming regression analysis; P < 0.05 was considered statistically significant. After excluding DNA values outside the linear range or without associated CMV antigenemia results, 516 results were included. The threshold DNA values corresponding to multiple CMV antigenemia values that are considered significant for a clinical decision at our institute were calculated. Youden index were determined through ROC curve analysis after excluding the upper 5% and lower 5% of DNA values, using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
The linear regression curves were analyzed using 516 results with significantly different intercepts in the child and adult groups (P = 0.02, Fig. 1 ). The predicted threshold values of CMV DNA that corresponded to clinically significant CMV antigenemia levels of 1, 5, 10, 15, 20, and 25 positive cells/2 × 10 5 white blood cells (WBCs) were 158, 316, 316, 1,122, 1,413, and 1,413 IU/ mL in children, and 158, 1,995, 2,512, 4,467, 4,467, and 6,310 IU/mL in adults, respectively. The proposed optimal thresholds of DNA values and their ability to predict the corresponding CMV antigenemia levels are presented in Table 1 .
Children and adults tend to differ significantly in physiology, metabolic state, physical size, body fluid compartments, and immune responses [4] . Thus, CMV replication kinetics evaluated by different targets (i.e., DNA or antigens) are likely to also differ according to age. Compared with adults, we found that children have significantly lower DNA values over a wide range of CMV antigenemia levels, including clinically significant levels.
Several studies have suggested various threshold DNA values for clinical decision-making depending on the sample used (whole blood [5, 8, 10] , plasma [3, 6] , and cells [9] ) and type of transplant (HSCT [6] [7] [8] [9] [10] and solid organ transplantation (SOT) [3, 6, 
7]
). SOT recipients tended to have higher DNA values than HSCT recipients [6, 7] . Boaretti, et al. [1] suggested 2,275 IU/mL as the threshold DNA value comparable to a CMV antigenemia level of 20 positive cells/2 × 10 5 WBCs, which differs strikingly from the 4,467 IU/mL threshold we determined. This difference could be due to variations in the sample type (plasma vs whole blood) or clinical conditions (SOT vs HSCT). These issues need to be further validated by standardization of the sample type for CMV Q-PCR analysis in different patient groups, and eventually by correlation with clinical course or outcome.
In conclusion, we found that relationships of CMV Q-PCR and CMV antigenemia test results differ significantly between children and adults who have undergone HSCT. Thus, threshold DNA values might need to be adjusted according to patient characteristics, to optimize anti-CMV therapeutic efficacy and improve the clinical outcome. 
